

Appendix 1: Voting frequency for trials ($N = 23$)

Trial	N	%
Systolic Blood Pressure Intervention Trial (SPRINT)	21	91
Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)	20	86
Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)	12	52
Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)	11	48
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)	9	39
Alberta Vascular Risk Reduction Community Pharmacy Project (Rx EACH)	6	26
Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE)	5	22
Heart Outcomes Prevention Evaluation (HOPE)-3	4	17
Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)	3	13
Intracoronary Stenting and Antithrombotic Regimen—Testing of a 6-Week Versus a 6-Month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-Eluting Stenting (ISAR-TRIPLE)	3	13
Reversal Effects of Idarucizumab on Active Dabigatran (RE-VERSE AD)	3	13
Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54)	2	9
Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery	2	9
Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA)	1	4
Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI)	1	4
Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA)	1	4
Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6)	0	0
Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY LONG TERM)	0	0
Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors (ANNEXA-4)	0	0

Appendix to: Barry AR, Babadagli HE, Basaraba JE, et al. Review of the top 5 cardiology studies of 2015-16. *Can Pharm J (Ott)* 2017;150(6). DOI: 10.1177/1715163517729835.